All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 800+ biotech and pharma professionals? Let’s chat. 👍

QUICK UPDATE
TLDR Biotech is taking a short break

Nothing to be worried about, I’m just taking some time off! But since it’s me writing these, that also means no TLDR Biotech for a wee bit. 😢

We’ll be back to our regularly scheduled TLDR Biotech posts starting September 16th. Toodles until then! ✌️

THE GOOD
Approvals & Labels

Emergent BioSolutions smallpox+mpox vaccine ACAM2000 handed expanded label by FDA for mpox prevention in high-risk individuals
Vaccine, monkeypox (mpox), smallpox, infectious disease - Read more

Renata Medical approves pediatric-specific stent that’s intended to expand in size as child grows
Medical device, stent, cardiovascular, congenital heart defect - Read more

THE GOOD
Business Development

Ipsen sells priority review voucher for $158M
Small molecule, priority review voucher - Read more

Jacobio Pharma grants China rights for glecirasib and JAB-3312 to Shanghai Allist Pharmaceuticals; $28M near term payments + $99M biobucks
Small molecule, cancer - Read more

THE GOOD
Clinical Trials

Lexaria Biosciences post positive safety data with “DehydraTECH” processed Rybelsus format
GLP-1, diabetes, oral format - Read more

Novo Nordisk reports pooled analysis for Wegovy in cardiovascular and worsening heart failure events
GLP-1, obesity, cardiovascular, heart failure - Read more

Novo Nordisk’s Wegovy tied to reduced death risk in COVID-19 patients; clinical trial analysis
GLP-1, obesity, covid-19 - Read more

THE GOOD
Fundraises

EVOQ Therapeutics $2M NIH grant
Drug delivery, antigen delivery, MOG antibody disease, autoimmune - Read more

THE GOOD
Investments

Merck & Co. (MSD) opens new London-based lab
Drug research & development - Read more [Paywall]

THE GOOD
Research

NIH grants $22M to 3 California-based universities to research extremophiles
Bacterial research, extremophiles - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Hutchmed pulls Elunate marketing application in China, citing survival data concerns
Small molecule, gastric or gastroesophageal junction adenocarcinoma, cancer - Read more

THE BAD
Clinical Trials

Alnylam reveals more Ph3 vutrisiran data which, though positive, misses some key details and doesn’t have physicians convinced
siRNA, transthyretin amyloidosis cardiomyopathy, cardiovascular - Read more

Merck & Co. discontinues two Keytruda Ph3 trials, citing disappointing interim data
Monoclonal antibody, lung cancer, carcinoma - Read more

NuCana shutters Ph2 NUC-3373 lung cancer trial due to unlikeliness of hitting primary endpoint
Small molecule, colorectal cancer - Read more

THE BAD
Earnings & Finances

ReNeuron leaves London’s AIM stock market after missing fundraising goal, enters administration
Stem cell, exosomes, drug delivery - Read more

THE BAD
Politics & Policy

Biosecure act US House vote slated for this month
Biosecure act - Read more

THE UGLY
No Ugly News today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.